Needham Downgrades NeoGenomics to Hold

Needham analyst Mike Matson downgrades NeoGenomics (NASDAQ:NEO) from Buy to Hold.

Needham analyst Mike Matson downgrades NeoGenomics (NASDAQ:NEO) from Buy to Hold.

Total
0
Shares
Related Posts